LARIMAR THERAPEUTICS, INC.

LRMR ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Assets
Cash & Equivalents $92.7M $177.9M $85.4M $90.1M $20.6M $21.1M $33.2M $35.1M
Accounts Receivable
Inventory
Total Current Assets $160.7M $205.0M $142.0M $183.2M $145.6M $165.5M $195.3M $213.3M
Property, Plant & Equipment $639.0K $558.0K $622.0K $709.0K $797.0K $855.0K $881.0K $779.0K
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $165.3M $208.5M $145.8M $187.4M $150.0M $170.2M $200.2M $219.0M
Liabilities
Accounts Payable $7.6M $8.6M $5.2M $11.1M $4.2M $2.3M $2.4M $1.7M
Total Current Liabilities $34.2M $47.8M $64.8M $45.1M $26.6M $22.1M $24.4M $16.3M
Long-Term Debt
Total Liabilities $37.9M $50.5M $67.8M $48.3M $30.1M $25.9M $28.4M $20.6M
Stockholders' Equity
Retained Earnings $-497.2M $-464.4M $-434.8M $-372.3M $-324.6M $-298.4M $-269.2M $-240.3M
Total Stockholders' Equity $127.4M $158.0M $78.1M $139.0M $119.9M $144.3M $171.8M $198.4M
← Newer Page 1 of 7 Older →